| Miss Meghan Mcmahon, | |
|
3703 W Lake Ave, Suite 200, Glenview, IL 60026-1223 | |
| (847) 998-1188 | |
| Not Available |
| Full Name | Miss Meghan Mcmahon |
|---|---|
| Gender | Female |
| Speciality | Speech-language Pathologist |
| Location | 3703 W Lake Ave, Glenview, Illinois |
| Accepts Medicare Assignments | Does not participate in Medicare Program. She may not accept medicare assignment. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1003235730 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 235Z00000X | Speech-language Pathologist | 242.002939 (Illinois) | Primary |
| Mailing Address | Practice Location Address |
|---|---|
| Miss Meghan Mcmahon, 680 S Federal St Apt 210, Chicago, IL 60605-1850 Ph: (734) 474-4129 | Miss Meghan Mcmahon, 3703 W Lake Ave, Suite 200, Glenview, IL 60026-1223 Ph: (847) 998-1188 |
News Archive
Anxiety sensitivity, in simple terms, is a fear of fear. But when people with anxiety sensitivity also have asthma, their suffering can be far more debilitating and dangerous, because they have difficulty managing their asthma. A new study explores this issue and recommends treatment to help decrease asthma symptoms.
Axxam (Milan), a leading provider of discovery services including assay development for high-throughput screening, and Cellectis bioresearch (Paris), the cell engineering expert, have started a collaboration to offer to the Life Science industry an extensive range of integrated discovery services based on genomic engineering technologies.
Electrical stimulation using extradural electrodes—placed underneath the skull but not implanted in the brain—is a safe approach with meaningful benefits for patients with Parkinson's disease, reports the October issue of Neurosurgery, official journal of the Congress of Neurological Surgeons.
Reata Pharmaceuticals and Abbott today announced data from a Phase 2b study which suggests that bardoxolone methyl, an investigational treatment for chronic kidney disease (CKD), may reduce the stage of CKD and improve estimated glomerular filtration rate (eGFR) and other measures of kidney function in the majority of patients receiving the drug.
RoActemra, which is the first innovation in the field for ten years, is being recommended for patients who have failed on standard treatments. It is the first time RoActemra has been approved for NHS patients in England and Wales with moderate to severe rheumatoid arthritis who are at an early stage in the disease. The drug has been available for early use in Scotland for two years.
› Verified 9 days ago
Ms. Kelly Watson Laughlin, SLP Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 2591 Compass Rd, Suite 100, Glenview, IL 60026 Phone: 847-729-6220 Fax: 847-729-1116 | |
Mrs. Karla Rae Faems, M.S.,CCC-SLP Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 3703 W Lake Ave, Suite 200, Glenview, IL 60026 Phone: 847-998-1188 | |
Allison M Raino, Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 1308 Waukegan Road, Suite 103, Glenview, IL 60025 Phone: 877-486-4140 | |
Miss Suzanne Michele Stroemer, MACCCSLP Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 3703 W Lake Ave, Suite 200, Glenview, IL 60026 Phone: 847-998-1188 | |
Janice Kim, Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 1920 Waukegan Rd Ste 212, Glenview, IL 60025 Phone: 404-917-4969 | |
Ashley Redwine, Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 2600 Compass Rd, Glenview, IL 60026 Phone: 877-787-3430 |